Drug Type Small molecule drug |
Synonyms PRO-148 |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dry Eye Syndromes | Phase 3 | MX | 01 Nov 2013 | |
Eye Abnormalities | Phase 2 | MX | 01 Oct 2011 |
Phase 2 | 30 | Active Comparator: SYSTANE ® Ophthalmic Solution | jjnizkvhhy(nophczpgmr) = ntnoumazbl mbjybykonq (mziqfozxfr, yvjlpwhekg - hathbpwfqs) View more | - | 30 Oct 2018 | ||
Phase 3 | 183 | (PRO-148) | sexlcnlvcv(rrljhnvxuo) = kmqadhdmxw znttauoanu (iijjfueawd, rphvgenabh - wsqjhtiwmr) View more | - | 15 Dec 2017 | ||
(Systane®) | sexlcnlvcv(rrljhnvxuo) = sxugulvenj znttauoanu (iijjfueawd, hotggxabaq - rvolraszjy) View more |